BioSpace4h
Just How Steep Is the Drug Patent Cliff? Ask These Pharmas
With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...
Fierce Pharma7d
AbbVie regained TV ad spending lead amid February slowdown, with Rinvoq and Skyrizi back on top
The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...
AbbVie (NYSE:ABBV) Expands SKYRIZI Availability In Canada For Ulcerative Colitis Treatment
AbbVie (NYSE:ABBV) recently announced the availability of its drug SKYRIZI® in Canada for treating adults with ulcerative ...
3 Dividend Stocks to Buy for Reliable Passive Income
You'll need passive income to live well in retirement, especially with Social Security's uncertain future. The Office of ...
Investing7d
AbbVie’s SWOT analysis: biopharmaceutical giant’s stock faces challenges and opportunities
AbbVie’s immunology portfolio, particularly Skyrizi and Rinvoq, has been instrumental in offsetting the decline in Humira sales. These two drugs have consistently outperformed expectations ...
pharmaphorum3d
AbbVie's Skyrizi beats IL-23 rivals to Crohn's disease approval
AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...
Investing6d
AbbVie’s SWOT analysis: biopharmaceutical giant’s stock faces challenges and opportunities
AbbVie’s immunology portfolio, particularly Skyrizi and Rinvoq, has been instrumental in offsetting the decline in Humira sales. These two drugs have consistently outperformed expectations, with ...
AbbVie Steps Into The Ring In The Obesity Drug Wars
AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue. Click to read why ABBV is a Hold.